Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy-Reference-Cited by-同舟云学术

Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy

Published:2024-07-02 Issue:3 Volume:31 Page:195-201
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Dima Danai¹,Hughes Michael²,Orland Mark³,Ullah Fauzia³,Goel Utkarsh¹,Anwer Faiz¹,Raza Shahzad¹,Mazzoni Sandra¹,Bhutani Divaya²,Williams Louis¹,Lentzsch Suzanne²,Samaras Christy¹,Valent Jason¹,Chakraborty Rajshekhar²,Khouri Jack¹

Affiliation:

1. Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA

2. Department of Hematology-Oncology, Columbia University, New York, NY, USA

3. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2024.2366806

Reference23 articles.

1. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation

2. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

3. Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

4. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis

5. Organ responses with daratumumab therapy in previously treated AL amyloidosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling monoclonal gammopathy of renal significance: a mini review on kidney complications and clinical insights;Frontiers in Nephrology;2024-09-12

2. Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis;American Journal of Hematology;2024-08-03